{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:12:45Z","timestamp":1790075565133,"version":"4.0.1"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jbo.2025.100680","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T14:21:55Z","timestamp":1743690115000},"page":"100680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Treatment of myeloma bone disease: When, how often, and for how long?"],"prefix":"10.1016","volume":"52","author":[{"given":"Michael Tveden","family":"Gundesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2025.100680_b0005","unstructured":"Rajkumar et. al. RSe. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet oncol. 2014;15:e538\u201348."},{"key":"10.1016\/j.jbo.2025.100680_b0010","doi-asserted-by":"crossref","unstructured":"Rebecca L. Siegel Angela N. Giaquinto AJD, PhD. Cancer statistics, 2024. CA Cancer J Clin. 2023;74.","DOI":"10.3322\/caac.21820"},{"issue":"1","key":"10.1016\/j.jbo.2025.100680_b0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc."},{"issue":"2","key":"10.1016\/j.jbo.2025.100680_b0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bmt.2009.155","article-title":"Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells","volume":"45","author":"Lioznov","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jbo.2025.100680_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010816.pub2","article-title":"Bortezomib for the treatment of multiple myeloma","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbo.2025.100680_b0030","doi-asserted-by":"crossref","unstructured":"T.A.H. Plesner, P. Gimsing, J. Krejcik, C. Lemech, M.C. Minnema, U. Lassen J.P. Laubach, A. Palumbo, S. Lisby, L. Basse, J. Wang, A.K. Sasser, M.E. Guckert, C. de Boer, N.Z. Khokhar, H. Yeh, P.L. Clemens, T. Ahmadi, H.M. Lokhorst, P.G. Richardson, Phase 1\/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. 128. 2016;14:1821-8.","DOI":"10.1182\/blood-2016-07-726729"},{"key":"10.1016\/j.jbo.2025.100680_b0035","article-title":"Bispecific antibodies in multiple myeloma treatment: A journey in progress","volume":"18","author":"Cho","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2025.100680_b0040","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s00277-024-05865-y","article-title":"Comorbidities and survival of multiple myeloma patients diagnosed in Finland between 2000 and 2021","volume":"103","author":"Kysenius","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jbo.2025.100680_b0045","unstructured":"https:\/\/www.kreftregisteret.no\/globalassets\/publikasjoner-og-rapporter\/arsrapporter\/publisert-2024\/arsrapport-2023-nasjonalt-kvalitetsregister-for-lymfoide-maligniteter.pdf. 2023."},{"issue":"6","key":"10.1016\/j.jbo.2025.100680_b0050","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3109\/0284186X.2013.875625","article-title":"Risk of disability pension for patients diagnosed with haematological malignancies: a register-based cohort study","volume":"53","author":"Horsboel","year":"2014","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.jbo.2025.100680_b0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jbo.2025.100680_b0060","first-page":"629","article-title":"Genetic control of bone formation","volume":"25","author":"Gerard Karsenty","year":"2009","journal-title":"Ann. Rev."},{"issue":"13","key":"10.1016\/j.jbo.2025.100680_b0065","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.3390\/ijms22136651","article-title":"Osteoblast differentiation and signaling: established concepts and emerging topics","volume":"22","author":"Ponzetti","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jbo.2025.100680_b0070","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2353\/ajpath.2007.060834","article-title":"Osteoclasts: what do they do and how do they do it?","volume":"170","author":"SL","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"5484","key":"10.1016\/j.jbo.2025.100680_b0075","first-page":"1504","article-title":"Bone resorption by osteoclasts","volume":"1","author":"Sl","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jbo.2025.100680_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2020.578477","article-title":"Control of bone matrix properties by osteocytes","volume":"11","author":"Creecy","year":"2021","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.jbo.2025.100680_b0085","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Lf","year":"2011","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.jbo.2025.100680_b0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2353\/ajpath.2009.080627","article-title":"A physical mechanism for coupling bone resorption and formation in adult human bone. . A physical mechanism for coupling bone resorption and formation in adult human bone","volume":"174","author":"Andersen","year":"2009","journal-title":"Am J Pathol."},{"key":"10.1016\/j.jbo.2025.100680_b0095","doi-asserted-by":"crossref","unstructured":"G D Roodman Cell biology of the osteoclast. Exp Hematol. 1999;28:1229-41.","DOI":"10.1016\/S0301-472X(99)00061-2"},{"issue":"13","key":"10.1016\/j.jbo.2025.100680_b0100","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"15","author":"Giuliani","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbo.2025.100680_b0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL Pathway in Multiple Myeloma","volume":"25","author":"Raje","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jbo.2025.100680_b0110","first-page":"2459","article-title":"The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease","volume":"19","author":"Bishop","year":"2024","journal-title":"Nat Commun."},{"key":"10.1016\/j.jbo.2025.100680_b0115","doi-asserted-by":"crossref","unstructured":"A.G.N.P. Robling, L.A. Baldridge, et al. . Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin. . J Biol Chem 2008;283:5866\u20137524.","DOI":"10.1074\/jbc.M705092200"},{"key":"10.1016\/j.jbo.2025.100680_b0120","doi-asserted-by":"crossref","unstructured":"W.C.V.N.B. Cheung, Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. 16. 2002;6:1182-8.","DOI":"10.1038\/sj.leu.2402481"},{"issue":"3","key":"10.1016\/j.jbo.2025.100680_b0125","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood.V98.3.771","article-title":"Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays","volume":"1","author":"De Vos","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jbo.2025.100680_b0130","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"issue":"6","key":"10.1016\/j.jbo.2025.100680_b0135","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.12761","article-title":"Mechanisms of bone destruction in multiple myeloma","volume":"26","author":"Terpos","year":"2017","journal-title":"Eur. J. Cancer Care."},{"key":"10.1016\/j.jbo.2025.100680_b0140","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jcp.2007.048868","article-title":"The cell biology of bone metabolism","volume":"61","author":"Datta","year":"2008","journal-title":"J Clin Pathol"},{"issue":"7","key":"10.1016\/j.jbo.2025.100680_b0145","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","volume":"1","author":"Giuliani","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jbo.2025.100680_b0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100680_b0155","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00256-008-0607-4","article-title":"Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI)","volume":"38","author":"Gleeson","year":"2009","journal-title":"Skeletal Radiol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100680_b0160","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/07357907.2013.764565","article-title":"Multiple myeloma lesion detection with whole body CT versus radiographic skeletal survey","volume":"31","author":"Princewill","year":"2013","journal-title":"Cancer Invest."},{"issue":"8","key":"10.1016\/j.jbo.2025.100680_b0165","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group","volume":"7","author":"Hillengass Lam","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jbo.2025.100680_b0170","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ejh.13749","article-title":"Lund T A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma","volume":"108","author":"Gundesen","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jbo.2025.100680_b0175","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2025.100680_b0180","doi-asserted-by":"crossref","unstructured":"R.A.R.S. Kyle. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009 Jan;23(1):3-9 2009;23(1):3-9.","DOI":"10.1038\/leu.2008.291"},{"key":"10.1016\/j.jbo.2025.100680_b0185","doi-asserted-by":"crossref","unstructured":"M.K. Andrew Chantry, Sally Barrington, Vicky Goh, Nicola Mulholland, Matthew Streetly, Maggie Lai, Guy Pratt,8 and on behalf of the British Society for Haematology Guidelines. Guidelines for the use of imaging in the management of patients with myeloma. Br. J. Haematol., 2017;178(380-393).","DOI":"10.1111\/bjh.14827"},{"issue":"6","key":"10.1016\/j.jbo.2025.100680_b0190","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2025.100680_b0195","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.0954-6820.1982.tb03234.x","article-title":"Evaluation of serial bone X-ray examination in multiple myeloma","volume":"212","author":"Wahlin","year":"1982","journal-title":"Acta Med. Scand."},{"issue":"7","key":"10.1016\/j.jbo.2025.100680_b0200","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: how? when?","volume":"133","author":"Elena Zamagni","year":"2019","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jbo.2025.100680_b0205","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2025.100680_b0210","doi-asserted-by":"crossref","unstructured":"S Vincent Rajkumar MAD, Antonio Palumbo, Joan Blade, Giampaolo Merlini, Mar\u00eda-Victoria Mateos, Shaji Kumar, Jens Hillengass, Efstathios Kastritis, Paul Richardson, Ola Landgren, Bruno Paiva, Angela Dispenzieri, Brendan Weiss, Xavier LeLeu, Sonja Zweegman, Sagar Lonial, Laura Rosinol, Elena Zamagni, Sundar Jagannath, Orhan Sezer, Sigurdur Y Kristinsson, Jo Caers, Saad Z Usmani, Juan Jos\u00e9 Lahuerta, Hans Erik Johnsen, Meral Beksac, Michele Cavo, Hartmut Goldschmidt, Evangelos Terpos, Robert A Kyle, Kenneth C Anderson, Brian G M Durie, Jesus F San Miguel. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538-48.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"issue":"11","key":"10.1016\/j.jbo.2025.100680_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11113088","article-title":"Newly diagnosed multiple myeloma patients with skeletal-related events and abnormal MRI pattern have poor survival outcomes: a prospective study on 370 patients","volume":"11","author":"Kanellias","year":"2022","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.jbo.2025.100680_b0220","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/10428194.2011.553000","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"52","author":"D'Arena","year":"2011","journal-title":"Leuk Lymphoma."},{"issue":"16","key":"10.1016\/j.jbo.2025.100680_b0225","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.2003.99.248","article-title":"Pamidronate for early-stage, untreated myeloma. Journal of clinical oncology : official journal of the","volume":"21","author":"Musto","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2025.100680_b0230","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"issue":"9757","key":"10.1016\/j.jbo.2025.100680_b0235","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2025.100680_b0240","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.jbo.2025.100680_b0245","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2025.100680_b0250","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"8827","key":"10.1016\/j.jbo.2025.100680_b0255","first-page":"1049","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Finnish Leukaemia Group. Lancet."},{"issue":"4","key":"10.1016\/j.jbo.2025.100680_b0260","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2011.04.004","article-title":"Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma","volume":"11","author":"Wu","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.jbo.2025.100680_b0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","article-title":"Bisphosphonate conjugation for bone specific drug targeting. . Bisphosphonate conjugation for bone specific drug targeting","volume":"3","author":"Farrell","year":"2018","journal-title":"Bone Rep."},{"issue":"8","key":"10.1016\/j.jbo.2025.100680_b0270","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jbo.2025.100680_b0275","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100680_b0280","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/10428194.2014.924117","article-title":"Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma","volume":"56","author":"Sanfilippo","year":"2015","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"10.1016\/j.jbo.2025.100680_b0285","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jbo.2025.100680_b0290","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jbo.2025.100680_b0295","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"LA Major","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jbo.2025.100680_b0300","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"17","key":"10.1016\/j.jbo.2025.100680_b0305","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s40265-016-0662-4","article-title":"Zoledronic Acid (Reclast(\u00ae), Aclasta(\u00ae)): a review in osteoporosis","volume":"76","author":"Dhillon","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jbo.2025.100680_b0310","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1345\/aph.1R776","article-title":"The role of denosumab for prevention of skeletal-related complications in multiple myeloma","volume":"47","author":"Hageman","year":"2013","journal-title":"Ann Pharmacother."},{"issue":"3","key":"10.1016\/j.jbo.2025.100680_b0315","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2025.100680_b0320","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.jbo.2025.100680_b0325","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1177\/2192568219884069","article-title":"Zoledronic acid versus denosumab for prevention of spinal cord compression in advanced cancers with spine metastasis: a meta-analysis of randomized controlled trials","volume":"10","author":"Al Farii","year":"2020","journal-title":"Global Spine J."},{"issue":"9","key":"10.1016\/j.jbo.2025.100680_b0330","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2025.100680_b0335","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/1060028016649368","article-title":"Identification of risk factors for bisphosphonate-associated atypical femoral fractures and osteonecrosis of the jaw in a pharmacovigilance database Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database","volume":"50","author":"Bejhed","year":"2016","journal-title":"Ann. Pharmacother."},{"issue":"10","key":"10.1016\/j.jbo.2025.100680_b0340","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.jcms.2017.07.014","article-title":"Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws - A retrospective cohort study","volume":"45","author":"Martins","year":"2017","journal-title":"Craniomaxillofac Surg."},{"issue":"8","key":"10.1016\/j.jbo.2025.100680_b0345","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2025.100680_b0350","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2025.100680_b0355","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Ascani3 & E. Cislaghi2. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.jbo.2025.100680_b0360","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk Lymphoma."},{"issue":"4","key":"10.1016\/j.jbo.2025.100680_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03795","article-title":"Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review","volume":"6","author":"Ottesen","year":"2020","journal-title":"Heliyon."},{"issue":"2","key":"10.1016\/j.jbo.2025.100680_b0370","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.oooo.2021.06.003","article-title":"Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: a randomized clinical feasibility trial of drug holiday versus drug continuation","volume":"133","author":"Ottesen","year":"2022","journal-title":"Oral Surg. Oral Med. Oral. Pathol. Oral Radiol."},{"key":"10.1016\/j.jbo.2025.100680_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115150","article-title":"Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider","volume":"130","author":"Tripto-Shkolnik","year":"2020","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.jbo.2025.100680_b0380","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jcm10010152","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"4","author":"Anastasilakis","year":"2021","journal-title":"J Clin Med."},{"issue":"2","key":"10.1016\/j.jbo.2025.100680_b0385","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","article-title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","volume":"22","author":"Ferrari-Lacraz","year":"2011","journal-title":"Osteoporosis Int."},{"issue":"1","key":"10.1016\/j.jbo.2025.100680_b0390","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporosis Int."},{"issue":"3","key":"10.1016\/j.jbo.2025.100680_b0395","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jbo.2025.100680_b0400","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2025.100680_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2018.100215","article-title":"Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data","volume":"14","author":"Kim","year":"2019","journal-title":"J. Bone Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2025.100680_b0410","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/leu.2013.267","article-title":"VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT","volume":"28","author":"Terpos","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jbo.2025.100680_b0415","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.25392","article-title":"Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates","volume":"94","author":"Terpos","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"9757","key":"10.1016\/j.jbo.2025.100680_b0420","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"on behalf of the National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jbo.2025.100680_b0425","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.2002.03824.x","article-title":"Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma","volume":"119","author":"Gordon","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100680_b0430","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.leu.2400892","article-title":"In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates","volume":"12","author":"Aparicio","year":"1998","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.jbo.2025.100680_b0435","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1007\/s00520-013-1934-0","article-title":"Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors","volume":"21","author":"Van den Wyngaert","year":"2013","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.jbo.2025.100680_b0440","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clml.2017.02.007","article-title":"Prolonged use of zoledronic acid (4 years) did not improve outcome in multiple myeloma patients","volume":"17","author":"Agustin Avil\u00e8s","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.jbo.2025.100680_b0445","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-024-01046-2","article-title":"In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease","volume":"14","author":"Lund","year":"2024","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.jbo.2025.100680_b0450","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","article-title":"Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial","volume":"100","author":"Garc\u00eda-Sanz","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jbo.2025.100680_b0455","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/1060028020967629","article-title":"Impact of extended-interval versus standard dosing of zoledronic acid on skeletal events in non-small-cell lung cancer and small-cell lung cancer patients with bone metastases","volume":"55","author":"Tam","year":"2021","journal-title":"Ann Pharmacother."},{"issue":"7","key":"10.1016\/j.jbo.2025.100680_b0460","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2025.100680_b0465","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2025.100680_b0470","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jbo.2025.100680_b0475","unstructured":"Andrew L. Himelstein M, Jared C. Foster, PhD, James L. Khatcheressian, MD, John D. Roberts, MD, Drew K. Seisler, BS, Paul J. Novotny, MS, Rui Qin, PhD, Ronald S. Go, MD, Stephen S. Grubbs, MD, Tracey O\u2019Connor, MD, Mario R. Velasco Jr, MD, Douglas Weckstein, MD, Ann O\u2019Mara, PhD, RN, MPH, Charles L. Loprinzi, MD, and Charles L. Shapiro, MD. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases. JAMA. 2017;03(48\u201358)."},{"issue":"6","key":"10.1016\/j.jbo.2025.100680_b0480","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/1078-0432.CCR-15-1864","article-title":"Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK Study","volume":"22","author":"Raje","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.jbo.2025.100680_b0485","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood-2013-04-498139","article-title":"The impact of response on bone-directed therapy in patients with multiple myeloma","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2025.100680_b0490","doi-asserted-by":"crossref","first-page":"S234","DOI":"10.1016\/S2152-2650(24)02251-1","article-title":"P-349 multiple myeloma patients who are in VGPR or better benefits from continued treatment with zoledronic acid beyond two years","volume":"24","author":"Lund","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.jbo.2025.100680_b0495","first-page":"105","article-title":"Nordic Myeloma Study Group. . Potential value of pre-planned imaging of bone disease in multiple myeloma. Blood","volume":"7","author":"Gundesen","year":"2023","journal-title":"Cancer J"},{"issue":"23","key":"10.1016\/j.jbo.2025.100680_b0500","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313144","article-title":"A cancer-related microRNA signature shows biomarker utility in multiple myeloma","volume":"22","author":"Papanota","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.jbo.2025.100680_b0505","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/leu.2010.173","article-title":"The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jbo.2025.100680_b0510","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated with osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.jbo.2025.100680_b0515","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jbo.2025.100680_b0520","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112768","article-title":"Daratumumab improves bone turnover in relapsed\/refractory multiple myeloma; phase 2 study \u201cREBUILD\u201d","volume":"14","author":"Terpos","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.jbo.2025.100680_b0525","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0609.2011.01599.x","article-title":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma","volume":"86","author":"TE Delforge","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jbo.2025.100680_b0530","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jbmr.4807","article-title":"Increased bone volume by ixazomib in multi-ple myeloma: 3-month results from an open label phase 2 Study. J Bone , * Diaz-delCastillo M GMasfa. Increased Bone Volume by Ixazomib in Multi-ple Myeloma: 3-Month Results from an Open Label Phase 2 Study","volume":"38","author":"Diaz-delCastillo","year":"2023","journal-title":"J Bone Miner Res."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137425000211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137425000211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T03:36:17Z","timestamp":1749699377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137425000211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":106,"alternative-id":["S2212137425000211"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100680","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of myeloma bone disease: When, how often, and for how long?","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2025.100680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100680"}}